The dermal toxicity testing market is a subset of toxicology that assesses the possible toxicity of chemicals on the skin. When applied topically, it entails evaluating the safety and efficacy of chemicals, cosmetics, medicines, and personal care products. This testing ensures consumer safety and regulatory compliance by assessing various cutaneous responses such as irritation, sensitization, and corrosion. The market is expected to witness significant growth due to prominently rising awareness of potential risks associated with substances applied to the skin. Moreover, stringent regulations from regulatory bodies like the FDA and ECHA have led to a strong demand for comprehensive dermal toxicity test services, ensuring the safety of consumers. Manufacturers conduct thorough assessments before introducing new chemical entities and products, further driving the market need.
Dermal toxicity testing employs several procedures, such as in vitro and in vivo approaches, to apply test compounds to the skin and assess their potential harmfulness. The primary objective is to provide valuable information about the risks associated with skin exposure, enabling the development and use of products that meet safety standards and regulatory requirements. Players are expanding their business in dermal toxicology. For instance, in January 2022, Eurofins announced the launch of its regulatory and toxicology expertise in France, allowing it to cater to higher number of clients.
The dermal toxicity market growth is also fueled by advancements in testing technologies, which have transformed the field of dermal toxicity assessment. Alternative test methods, including reconstructed human epidermis models and cell culture-based assays, have gained prominence as they provide accurate and reliable results while addressing ethical concerns related to animal testing. Moreover, the development of in vitro testing systems, predictive toxicology models, and advanced computational approaches has significantly improved the efficiency and effectiveness of dermal toxicity testing, propelling the market forward.
In addition to these factors, in January 2021, EPA finalizing guidance to waive animal skin toxicity tests further promotes the use of alternative methods in dermal toxicity assessment and reduces reliance on animal testing. This advancement aligns with the growing emphasis on finding alternative approaches to ensure safety while minimizing the use of animals in test procedures. Overall, the combination of increased awareness, regulatory requirements, technological advancements, and the promotion of alternative methods underscores the positive trajectory of the market.
The dominance of North America in the market can be attributed to its robust regulatory framework, presence of major industries, focus on research and innovation, and consumer demand for safe products. The stringent guidelines and regulations set by the FDA create a strong demand for comprehensive test services. At the same time, the pharmaceuticals, cosmetics, and chemicals industries heavily rely on testing for product safety and regulatory compliance. The region's research and development infrastructure and commitment to innovation enable it to stay at the forefront of test technologies, including alternative methods to reduce animal testing. Additionally, consumer awareness and the growing emphasis on product safety contribute to North America's prominent position in the market.
Skin Irritation Tests, Skin Sensitization Tests, Skin Corrosion Tests, Phototoxicity Tests
Testing Method Type
In Vivo Testing (Animal-Based Tests) and In Vitro Testing (Cell-Based or Tissue-Based Tests)
Pharmaceuticals industries, Cosmetics and personal care products industry, Chemical Industry and Other.
Major companies operating in the dermal toxicity testing market include Charles River Laboratories, Covance Inc., Eurofins Scientific, Intertek Group plc, and others. These players focus on geographical expansion and product launches to maintain their presence in the market. For instance, in March 2022, Virpax completed all necessary pre-clinical studies, including dermal toxicity, for their investigational topical spray analgesic product, Epoladerm. This product aims to manage chronic pain associated with knee osteoarthritis, potentially relieving patients.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."